Johnson & Johnson anticipates two critical FDA decisions in 2026. These approvals could increase the company's market capitalization by an estimated $10 billion. The new products may generate between $2 billion and $3 billion in combined annual revenue.
The first decision for a hematological cancer drug is expected by the third quarter of 2026. This oncology treatment targets a market valued at $5 billion annually. The second decision for an infectious disease vaccine is anticipated in the fourth quarter of 2026. This vaccine addresses a global market worth approximately $3 billion per year. Both products demonstrated high efficacy during clinical trials.